CP-CTNet_CLO-MD Anderson A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome Cancer Prevention and Control CIRB Active Available to Open